跳至內容

3-羥基芬納西泮

維基百科,自由的百科全書
3-羥基芬納西泮
臨床資料
ATC碼
  • 未分配
法律規範狀態
法律規範
識別資訊
  • 7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one
CAS號70030-11-4
PubChem CID
ChemSpider
UNII
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
化學資訊
化學式C15H10BrClN2O2
摩爾質量365.61 g·mol−1
3D模型(JSmol英語JSmol
  • c1ccc(c(c1)C2=NC(C(=O)Nc3c2cc(cc3)Br)O)Cl
  • InChI=1S/C15H10BrClN2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)
  • Key:KRJKJUWAZOWXNV-UHFFFAOYSA-N

3-羥基芬納西泮英語:3-Hydroxyphenazepam),或叫3-羥基苯那西泮,是一種苯二氮䓬類藥物,具有催眠鎮靜抗焦慮抗驚厥作用。[1]它是芬納西泮活性代謝物[1][2]也是苯二氮䓬類藥物前藥西那西泮的活性代謝物。[3]相對於芬納西泮,3-羥基芬納西泮具有微弱的肌肉鬆弛特性,但在大多數其他方面大致相當。[1]與其他苯二氮卓類藥物一樣,3-羥基芬納西泮可作為GABAA受體苯二氮䓬類位點的正向變構調節劑,EC50值為10.3nM。[4][5][6]它曾作為設計師藥物在網上銷售。[7][8][9][10]

參見

[編輯]

參考資料

[編輯]
  1. ^ 1.0 1.1 1.2 Artur Viktorovich Valʹdman. Drug dependence and emotional behavior: neurophysiological and neurochemical approaches. Consultants Bureau. 31 May 1986. ISBN 978-0-306-10984-3. 
  2. ^ Lukasz Komsta; Monika Waksmundzka-Hajnos; Joseph Sherma. Thin Layer Chromatography in Drug Analysis. CRC Press. 20 December 2013: 299–. ISBN 978-1-4665-0715-9. 
  3. ^ Schukin SI, Zinkovsky VG, Zhuk OV. Elimination kinetics of the novel prodrug cinazepam possessing psychotropic activity in mice (PDF). Pharmacol Rep. 2011, 63 (5): 1093–100 [2023-02-14]. PMID 22180351. doi:10.1016/s1734-1140(11)70628-4. (原始內容存檔 (PDF)於2022-10-12). 
  4. ^ Phenazepam Pre-Review Report (PDF). World Health Organization (WHO). November 2015 [2023-02-14]. (原始內容存檔 (PDF)於2022-01-20). 
  5. ^ Kopanitsa, M. V.; Zbarska, S. M.; Boychuk, Ya. A.; Krishtal, O. A. Modulation of GABA-activated currents by phenazepam and its metabolites in isolated rat purkinje neurons. Neurophysiology. 2000, 32 (3): 192. ISSN 0090-2977. S2CID 32313668. doi:10.1007/BF02506568. 
  6. ^ Golovenko, N. Ya; Larionov, V. B. Pharmacodynamical and Neuroreceptor Analysis of the Permeability of the Blood-Brain Barrier for Derivatives of 1,4-Benzodiazepine. Neurophysiology. 2014, 46 (3): 199–205. ISSN 0090-2977. S2CID 33732669. doi:10.1007/s11062-014-9429-2. 
  7. ^ 3-hydroxyphenazepam. New Synthetic Drugs Database. [2016-05-30]. (原始內容存檔於2016-09-28). 
  8. ^ Madeleine Pettersson Bergstrand; Anders Helander; Therese Hansson; Olof Beck. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. Drug Testing and Analysis. 2016, 9 (4): 640–645. PMID 27366870. doi:10.1002/dta.2003. 
  9. ^ Moosmann, Bjoern; Bisel, Philippe; Franz, Florian; Huppertz, Laura M.; Auwärter, Volker. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines – an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam, and nitrazolam. Journal of Mass Spectrometry. 2016, 51 (11): 1080–1089. Bibcode:2016JMSp...51.1080M. ISSN 1096-9888. PMID 27535017. doi:10.1002/jms.3840. 
  10. ^ Manchester, Kieran R.; Maskell, Peter D.; Waters, Laura. Experimental versus theoretical log D7.4, pKa and plasma protein binding values for benzodiazepines appearing as new psychoactive substances (PDF). Drug Testing and Analysis. 2018, 10 (8): 1258–1269 [2023-02-14]. ISSN 1942-7611. PMID 29582576. doi:10.1002/dta.2387. (原始內容存檔 (PDF)於2021-08-02).